Search
Connecticut Paid Clinical Trials
A listing of 1248 clinical trials in Connecticut actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
541 - 552 of 1248
Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Intracranial Meningioma, Grade 2 Meningioma
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery.
The name of the study drugs involved are:
* Trastuzumab-emtansine (T-DM1, Kadcyla)
* Trastuzumab SC (Herceptin Hylecta)
* Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2025
Locations: Smilow Cancer Hospital Care center at Derby, Derby, Connecticut
Conditions: Breast Cancer, HER2-positive Breast Cancer
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Recruiting
This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow do... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Hematopoietic and Lymphatic System Neoplasm
Community Health Equity Accelerator (CHEA) Pediatric Asthma Intervention
Recruiting
The purpose of this pilot is to initiate an academic-community partnership and launch a multi-level intervention that includes an asthma exposure pathway (an online decision support and resource) and a health Promotora program that will provide culturally responsive asthma support alongside legal and medical services to improve access to asthma care and ultimately improve asthma-related outcomes in the New Haven region.
Gender:
ALL
Ages:
Between 4 years and 11 years
Trial Updated:
07/11/2025
Locations: Yale, New Haven, Connecticut
Conditions: Asthma in Children
Simulation Trial of Telemedical Support for Paramedics
Recruiting
In the United States, the current standard of prehospital (i.e. outside of hospitals) emergency care for children with life-threatening illnesses in the community includes remote physician support for paramedics providing life-saving therapy while transporting the child to the hospital. Most prehospital emergency medical services (EMS) agencies use radio-based (audio only) communication between paramedics and physicians to augment this care. However, this communication strategy is inherently lim... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/11/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Cardiopulmonary Arrest, Acute Respiratory Failure, Status Epilepticus, Emergencies
Impact of Family-Centered Care for Intimate Partner Violence (IPV)
Recruiting
The purpose of the study will be to determine how participation in Family-Centered Care (FCC) compared to Child-centered care (CCC) will affect caregiver engagement in IPV-based community services, caregiver perceptions of empowerment and survivor-defined practice, and clinical outcomes for children exposed to IPV.
Gender:
ALL
Ages:
All
Trial Updated:
07/11/2025
Locations: SCAN Clinic, Hartford, Connecticut
Conditions: Intimate Partner Violence
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, New Haven, Connecticut
Conditions: Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Norwalk, Connecticut
Conditions: Major Depressive Disorder
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Recruiting
The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. The exercise therapy in this study will be regular home-based walking sessions on a treadmill, and that therapy will be assigned by an exercise physiologist (a medical professional who studies how exercise affects the human body). Some participants in this study will have the assigned exercise therapy, and some participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Hartford Healthcare Alliance (Data collection only), Hartford, Connecticut
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Yale University Multiple Sclerosis Center, New Haven, Connecticut
Conditions: Multiple Sclerosis
